CytRx (CYTR) Reports Positive Secondary Endpoint Results from Aldoxorubicin Combo Phase 2b
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Wall St ticks up on megacaps, earnings boost
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Wall St turns higher, gold climbs, oil dips amid economic, geopolitical crosswinds
- US dollar modestly firmer after strong data, Fed comments
- Oil steadies as new sanctions interrupt easing tensions
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
Aegis Affirms CytRx (CYTR) at 'Buy' Following Aldoxorubicin Phase 2b OS Update
January 23, 2015 10:20 AM ESTAegis Capital affirms CytRx (NASDAQ: CYTR) at Buy with a price target of $12 after the company announced encouraging overall survival (OS) results, the secondary endpoint,... More
CytRx (CYTR) Reports Removal of FDA Partial Clinical Hold on Aldoxorubicin Tests
January 20, 2015 6:56 AM ESTCytRx (NASDAQ: CYTR) announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites' Institutional Review Boards (IRBs) approve the revised trial... More
